Laboratory Corp American Holdings is a leading global life sciences company that offers comprehensive laboratory services, including diagnostic testing and drug development support. They operate advanced clinical laboratories that conduct a wide array of tests, specializing in areas such as genetics, infectious diseases, and routine screenings. The company also provides end-to-end solutions for the pharmaceutical and biotechnology industries, assisting in the development of new therapies and drugs through clinical trial testing and regulatory support. By leveraging cutting-edge technology and a vast network of resources, Laboratory Corp aims to improve healthcare outcomes and enhance patient care through accurate and timely laboratory results. Read More
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Labcorp’s Q4 results came in below Wall Street’s revenue expectations, leading to a negative market reaction, while management attributed performance to strength in specialty testing and expanded partnerships with hospitals and regional labs. CEO Adam Schechter highlighted the company’s double-digit growth in esoteric testing and the successful integration of recent acquisitions, including Invitae and assets from various health systems. Schechter also acknowledged that lower organic volume growth was partly due to reduced referrals from a major consumer genetic client and mild weather disruptions, but indicated these were largely isolated events. The quarter was further supported by ongoing cost discipline and advancements in automation and artificial intelligence across core laboratory and consumer services.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.7 billion at the midpoint. Its non-GAAP profit of $4.07 per share was 3.2% above analysts’ consensus estimates.
Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH)
fell 2.7% in the afternoon session after the company reported fourth-quarter revenue that fell short of Wall Street's expectations, overshadowing an earnings beat.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.7 billion at the midpoint. Its non-GAAP profit of $4.07 per share was 3.2% above analysts’ consensus estimates.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH)
will be announcing earnings results this Tuesday before market hours. Here’s what investors should know.
On February 11, 2026, the clinical laboratory landscape is recalibrating following a whirlwind 48 hours of financial and regulatory news. Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, finds itself at the epicenter of this shift. Following a blowout fourth-quarter earnings report yesterday and a last-minute legislative reprieve regarding Medicare reimbursement [...]
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Today, Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomoniasis from the comfort and privacy of the home.
In the complex ecosystem of modern medicine, few companies carry as much institutional weight—or stir as much controversy—as Charles River Laboratories International, Inc. (NYSE: CRL). As of December 23, 2025, Charles River stands as the indispensable backbone of the global pharmaceutical industry. It is a company that has, remarkably, participated in the development of over [...]
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately -
over the past six months, healthcare stocks have gained 13.5%, nearly mirrorring the S&P 500.
Since June 2025, Labcorp has been in a holding pattern, posting a small return of 1% while floating around $258.38. The stock also fell short of the S&P 500’s 14.1% gain during that period.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Community Health Systems, Inc. (the “Company”) (NYSE: CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has completed the sale of select assets of the ambulatory outreach laboratory services of CHS-affiliated health systems in 13 states, including certain patient service centers and in-office phlebotomy locations, to Labcorp (NYSE: LH) for approximately $194 million cash, before certain transaction expenses.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industry, including Labcorp (NYSE:LH) and its peers.
